Abstract:Background: The clinical course of ischemic and hemorrhagic strokes can be influenced by the coagulation status of individual patients. The prior use of antiplatelet therapy (APT) such as acetylsalicylic acid (ASA) or P2Y12-antagonists has been inconsistently described as possibly increasing the risk of hemorrhagic transformation or expansion. Since clinical studies describing prior use of antiplatelet medication are overwhelmingly lacking specific functional tests, we aimed to implement testing in routine stroke care. Methods: We used fluorescence-activated cell sorting (FACS) with antibodies against CD61 for thrombocyte identification and CD62p or platelet activation complex-1 (PAC-1) to determine platelet activation. Aggregometry and automated platelet functioning analyzer (PFA-200) were employed to test thrombocyte reactivity. FACS and aggregometry samples were stimulated in vitro with arachidonic acid (AA) and adenosine diphosphate (ADP) to measure increase in CD62p-/PAC-1-expression or aggregation, respectively. Results: Between February and July 2023, 20 blood samples ( n = 11 ischemic strokes; n = 7 hemorrhagic strokes; n = 2 controls) were acquired and analyzed within 24 h of symptom onset. N = 11 patients had taken ASA, n = 8 patients no APT and n = 1 ASA+clopidogrel. ASA intake compared to no APT was associated with lower CD62p expression after stimulation with AA on FACS analysis (median 15.8% [interquartile range {IQR} 12.6–37.2%] vs. 40.1% [IQR 20.3–56.3%]; p = 0.020), lower platelet aggregation (9.0% [IQR 7.0–12.0%] vs. 88.5% [IQR 11.8–92.0%]; p = 0.015) and longer time to plug formation with PFA-200 (248.0 s [IQR 157.0–297] vs. 121.5 s [IQR 99.8–174.3]; p = 0.027). Significant correlations were noted between AA-induced CD62p expression and aggregometry analysis ( n = 18; ρ = 0.714; p < 0.001) as well as a negative correlation between CD62p increase and PFA clot formation time ( n = 18; ρ = −0.613; p = 0.007). Sensitivity for ASA intake was highest for PFA (81.8% for values ≥155.5 s). The combination of ASA + clopidogrel also affected ADP-induced CD62p and PAC-1 expression. Conclusion: In the clinical setting it is feasible to use differentiated platelet analytics to determine alterations caused by antiplatelet therapy. Among the tests under investigation, PFA-200 showed the highest sensitivity for the intake of ASA in stroke patients. FACS analysis on the other hand might be able to provide a more nuanced approach to altered platelet reactivity.

The Effects of Antiplatelet Agents on Platelet–leukocyte Aggregations in Patients with Acute Cerebral Infarction

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Study on expression of platelet membrane glycoproteins in cerebral infarction with carotid atherosclerosis

Safety of Early Antiplatelet Therapy for Non-Cardioembolic Mild Stroke Patients with Thrombocytopenia.

The Influence of the Anti-platelet Drugs on Platelet Activation of the Patients with Acute Cerebral Infarction

The Research about the State of the Activated Blood Platelet of Cerebral Infarction Patients

Effects of Puerarin with Aspirin on the Markers of Damaged Vascular Endothelial Cells in Patients with Acute Cerebral Infarction

Efficacy of Monitoring Platelet Function by an Automated PL-12 Analyzer During the Treatment of Acute Cerebral Infarction With Antiplatelet Medicine

Quantitative Analysis of Platelet Function in Acute Cerebral Infarction

Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status.

Differences in platelet–leukocyte aggregates among subtypes of acute cerebral ischemia

Comparison of Flow Cytometry,ELISA and Thrombelastograph Monitoring Antiplatelet Therapy in Patients with Acute Cerebral Infarction

Changes of plasma biomolecules in patients with acute cerebral infarction before and after treatment

The impact of various antiplatelet strategies on the incidence of gouty arthritis in hospitalized patients with acute cerebral infarction

Feasibility and comparability of different platelet function tests in acute stroke with or without prior antiplatelet therapy

Effects of Antiplatelet Agents on Functional Outcome and Cognitive Status in Patients with Acute Ischemic Stroke

Investigation of the relation between platelet activation and ischemic stroke disease

Effect of Clopidogrel combined with aspirin in the treatment of acute progressive cerebral infarction: A retrospective single-center analysis

Effects of antiplatelet agents on platelet function with arteriosclerosis obliterans patients of type 2 diabetes mellitus

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel